GlobeImmune (GBIM) Shares are Down -4.32%

GlobeImmune (GBIM) : During the past 4 weeks, traders have been relatively bearish on GlobeImmune (GBIM), hence the stock is down -62.24% when compared to the S&P 500 during the same period. However, in the past 1 week, the selling of the stock is down by -4.9% relative to the S&P 500. The 4-week change in the price of the stock is -59.69% and the stock has fallen -4.32% in the past 1 week.

GlobeImmune (NASDAQ:GBIM): The stock opened at $0.94 on Friday but the bulls could not build on the opening and the stock topped out at $1.15 for the day. The stock traded down to $0.85 during the day, due to lack of any buying support eventually closed down at $0.87 with a loss of -6.38% for the day. The stock had closed at $0.93 on the previous day. The total traded volume was 883,958 shares.


The stock has recorded a 20-day Moving Average of 35.07% and the 50-Day Moving Average is 38.19%. GlobeImmune Inc. has dropped 57.94% during the last 3-month period . Year-to-Date the stock performance stands at -77.5%.

GlobeImmune, Inc. (GlobeImmune) is a biopharmaceutical company. The Company is focused on developing therapeutic products for cancer and infectious diseases based on its Tarmogen platform. The Company has four Tarmogen product candidates in five ongoing clinical trials. The Company has two collaborations with biotechnology companies. Gilead Sciences, Inc. (Gilead), exclusively licenses product candidates to treat chronic hepatitis B virus (HBV) infection. Celgene Corporation (Celgene) entered into collaboration with the Company for certain oncology product candidates. Celgene exercises its option for across the world, exclusive license to the GI-6300 program, which is a Tarmogens program targeting the brachyury protein. The Company has no products approved for commercial sale, and as of September 30, 2014, it has not generated any product revenue.

Comments (0)

Leave a Reply

Your email address will not be published. Required fields are marked *

Get Pre-Market Alerts!

Get Pre-Market Analysts' Upgrades, Downgrades, Earnings & Initiations with our FREE daily email newsletter.